MedPath

Clomipramine

Generic Name
Clomipramine
Brand Names
Anafranil
Drug Type
Small Molecule
Chemical Formula
C19H23ClN2
CAS Number
303-49-1
Unique Ingredient Identifier
NUV44L116D
Background

Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H receptors, α-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Clomipramine may be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourette’s disorder). Unlabeled indications include panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy, autistic disorder, trichotillomania, onchophagia, stuttering, premature ejaculation, and premenstrual syndrome. Clomipramine is rapidly absorbed from the gastrointestinal tract and demethylated in the liver to its primary active metabolite, desmethylclomipramine.

Indication

May be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourette’s disorder).

Unlabeled indications include: depression, panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy (limited evidence), autistic disorder (limited evidence), trichotillomania (limited evidence), onchophagia (limited evidence), stuttering (limited evidence), premature ejaculation, and premenstrual syndrome.

Associated Conditions
Depression, Obsessive Compulsive Disorder (OCD), Panic Disorder

Pharmacovigilance in Gerontopsychiatric Patients

Phase 3
Terminated
Conditions
Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders
Interventions
First Posted Date
2015-03-02
Last Posted Date
2018-02-28
Lead Sponsor
Hannover Medical School
Target Recruit Count
407
Registration Number
NCT02374567
Locations
🇩🇪

Bezirkskrankenhaus Augsburg, Augsburg, Germany

🇩🇪

Krankenhaus Hedwigshöhe, Berlin, Germany

🇩🇪

Hannover Medical School, Hannover, Germany

and more 2 locations

Interpersonal Psychotherapy for Treatment Resistant Depression

First Posted Date
2013-07-11
Last Posted Date
2013-07-11
Lead Sponsor
Hospital de Clinicas de Porto Alegre
Target Recruit Count
74
Registration Number
NCT01896349
Locations
🇧🇷

Federal University of Rio Grande do Sul / Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil

Citalopram vs Clomipramine vs Placebo in Recurrent Depression

Not Applicable
Completed
Conditions
Depression
Interventions
First Posted Date
2012-04-11
Last Posted Date
2012-04-11
Lead Sponsor
University of Aarhus
Target Recruit Count
59
Registration Number
NCT01575158

Trial of PED-1 in Male Patients With Premature Ejaculation

Phase 3
Completed
Conditions
Premature Ejaculation
Interventions
First Posted Date
2011-09-23
Last Posted Date
2012-10-03
Lead Sponsor
Symyoo
Target Recruit Count
159
Registration Number
NCT01439984
Locations
🇰🇷

Inje University Ilsan Paik Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of

🇰🇷

National Health Insurance Corporation Ilsan Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of

🇰🇷

Uijeongbu St.Marry's Hospital, Uijeongbu-si, Gyeonggi-do, Korea, Republic of

and more 2 locations

Predicting Medication Response in Obsessive Compulsive Disorder

Not Applicable
Completed
Conditions
Obsessive Compulsive Disorder
Interventions
First Posted Date
2011-07-28
Last Posted Date
2013-01-31
Lead Sponsor
Sunnybrook Health Sciences Centre
Target Recruit Count
26
Registration Number
NCT01404871
Locations
🇨🇦

Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

🇨🇦

The Centre for Addiction and Mental Health, Toronto, Ontario, Canada

Phase 2 Trial of PED-1 and PED-2 in Male Patients With Premature Ejaculation

Phase 2
Completed
Conditions
Premature Ejaculation
Interventions
First Posted Date
2010-09-16
Last Posted Date
2012-10-03
Lead Sponsor
Symyoo
Target Recruit Count
104
Registration Number
NCT01203202
Locations
🇰🇷

Ewha University Mok-dong Hospital, Seoul, Korea, Republic of

🇰🇷

Seoul St. Marry's Hospital, Seoul, Korea, Republic of

Quetiapine Augmentation Versus Clomipramine Augmentation of SSRI for Obsessive-compulsive Disorder Patients

Phase 4
Completed
Conditions
Obsessive Compulsive Disorder
Interventions
First Posted Date
2007-11-28
Last Posted Date
2017-10-27
Lead Sponsor
University of Sao Paulo
Target Recruit Count
21
Registration Number
NCT00564564
Locations
🇧🇷

Institute of Psychiatry, Clinics Hospital, University of São Paulo Medical School, São Paulo, SP, Brazil

Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment

Phase 4
Completed
Conditions
Obsessive Compulsive Disorder
Interventions
First Posted Date
2007-04-27
Last Posted Date
2017-10-30
Lead Sponsor
University of Sao Paulo
Target Recruit Count
54
Registration Number
NCT00466609
Locations
🇧🇷

Institute of Psychiatry, Sao Paulo, SP, Brazil

Phase II Randomized Study of Intravenous Versus Oral Clomipramine in Patients With Obsessive Compulsive Disorder

Phase 2
Conditions
Obsessive-Compulsive Disorder
First Posted Date
1999-10-19
Last Posted Date
2005-06-24
Lead Sponsor
National Center for Research Resources (NCRR)
Target Recruit Count
76
Registration Number
NCT00004310
Locations
🇺🇸

Stanford University Medical Center, Stanford, California, United States

🇺🇸

University of Cincinnati Medical Center, Cincinnati, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath